Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53-MDM2 inhibitors are investigated for TP53 wild-type (WT) tumors.
• Patient selection for these therapies remains a challenge as not all TP53 WT tumors respond.
• A 13-gene mRNA expression signature was developed to predict response in TP53 WT tumors.

Purpose of the Study:

• To validate the predictive capability of a 13-gene mRNA expression signature for TP53-MDM2 inhibitor response.
• To re-evaluate TP53 mutational status in cell lines used for signature validation.

Main Methods:

• Reanalysis of TP53 status in a validation dataset of cancer cell lines.
• Assessment of the 13-gene signature's ability to predict response to TP53-MDM2 inhibitors in TP53 WT cell lines.

Main Results:

• TP53 inactivating alterations were detected in 23% of cell lines initially classified as TP53 WT.
• The 13-gene signature did not accurately predict response to TP53-MDM2 inhibitors in the remaining TP53 WT cell lines.

Conclusions:

• The 13-gene mRNA expression signature is not a reliable predictor of TP53-MDM2 inhibitor response in TP53 WT tumors.
• Accurate TP53 status determination is critical for patient stratification in targeted cancer therapy.
• Further research is needed to identify reliable biomarkers for predicting response to TP53-MDM2 inhibitors.